Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6721 AL 6735

[Drug therapy for Alzheimer's disease]

Shoji M.

Brain Nerve. 2010 Jul;62(7):777-85.

Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality

Ballard C, Creese B, Corbett A, Aarsland D.

Expert Opin Drug Saf. 2011 Jan;10(1):35-43. doi: 10.1517/14740338.2010.506711. Epub 2010 Aug 5.

Third degree heart block following intramuscular ziprasidone

Tambyraja R, Strawn JR.

Schizophr Res. 2011 Feb;125(2-3):302-3. doi: 10.1016/j.schres.2010.07.015. Epub 2010 Aug 7.

Why are drug trials in Alzheimer's disease failing?

Lancet. 2010 Aug 28;376(9742):658. doi: 10.1016/S0140-6736(10)61316-5.

Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: a preliminary report

Na HR, Kim S, Choi SH, Yang DW, Bae HJ, Kim JE, Park MY, Shim YS, Kim BK, Kwon JC, Yoo BG, Kim BC, Lee JS.

Geriatr Gerontol Int. 2011 Jan;11(1):90-7. doi: 10.1111/j.1447-0594.2010.00649.x. Epub 2010 Sep 3.

Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial

Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SSh, Yousefi MH, Alimardani R, Jamshidi A, Zare F, Moradi A.

J Clin Pharm Ther. 2010 Oct;35(5):581-8. doi: 10.1111/j.1365-2710.2009.01133.x.

A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease

Geldmacher DS, Fritsch T, McClendon MJ, Landreth G.

Arch Neurol. 2011 Jan;68(1):45-50. doi: 10.1001/archneurol.2010.229. Epub 2010 Sep 13.

Estrogen therapy and Alzheimer's dementia

Craig MC, Murphy DG.

Ann N Y Acad Sci. 2010 Sep;1205:245-53. doi: 10.1111/j.1749-6632.2010.05673.x.

In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease

Yokokura M, Mori N, Yagi S, Yoshikawa E, Kikuchi M, Yoshihara Y, Wakuda T, Sugihara G, Takebayashi K, Suda S, Iwata Y, Ueki T, Tsuchiya KJ, Suzuki K, Nakamura K, Ouchi Y.

Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):343-51. doi: 10.1007/s00259-010-1612-0. Epub 2010 Sep 16.

Why is the New York Times writing so much about Alzheimer's disease therapies?

Bartfai T.

ScientificWorldJournal. 2010 Sep 14;10:1886-9. doi: 10.1100/tsw.2010.185.

Anesthetics and tau protein: animal model studies

Run X, Liang Z, Gong CX.

J Alzheimers Dis. 2010;22 Suppl 3:49-55. doi: 10.3233/JAD-2010-100813.

Studies in animal models of the effects of anesthetics on behavior, biochemistry, and neuronal cell death

Mena MÁ, Perucho J, Rubio I, de Yébenes JG.

J Alzheimers Dis. 2010;22 Suppl 3:43-8. doi: 10.3233/JAD-2010-100822.

Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease

Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, Cowart MD.

J Pharmacol Exp Ther. 2011 Jan;336(1):38-46. doi: 10.1124/jpet.110.166876. Epub 2010 Sep 23.

Naltrexone effects in patients with dementia

Read SL.

Am J Psychiatry. 2010 Oct;167(10):1278-9. doi: 10.1176/appi.ajp.2010.09111630.

A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease

Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, Dixon IJ, Hallett WA, Whitcher B, Brown AP, Zvartau-Hind M, Lotay N, Lai RY, Castiglia M, Jeter B, Matthews JC, Chen K, Bandy D, Reiman EM, Gold M, Rabiner EA, Matthews PM.

J Alzheimers Dis. 2010;22(4):1241-56. doi: 10.3233/JAD-2010-100939.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias